

ISO/TR 22442-4:2010-12 (E)

Medical devices utilizing animal tissues and their derivatives - Part 4: Principles for elimination and/or inactivation of transmissible spongiform encephalopathy (TSE) agents and validation assays for those processes

Contents	Page
Foreword	iv
Introduction	v
1 Scope	1
2 Normative references	1
3 Terms and definitions	2
4 Elimination of TSE agents: basic considerations	2
4.1 General	2
4.1.1 TSEs of concern	2
4.1.2 Animal tissues of concern	2
4.1.3 Tissues infected with TSE agents	2
5 Potential methods to eliminate TSE agents	3
5.1 Methods for inactivating infectivity	3
5.1.1 General	3
5.1.2 Physical methods for inactivating TSE infectivity	3
5.1.3 Chemical methods for inactivating TSE infectivity	4
5.2 Methods for removing TSE infectivity without inactivating infectivity	5
6 Experimental validation of methods for eliminating TSE agents from medical devices utilizing non-viable animal tissues	6
6.1 General	6
6.2 Defining of product families for purposes of designing TSE process validation studies	6
6.3 Selection and testing of product for establishing and verifying the infecting dose of TSE agent	6
6.4 TSE agent spiking materials	6
6.5 Availability of bioassay animals (conventional and transgenic mice, other rodents, farm animals)	7
6.6 Potential development of cell culture assays for infectivity	7
6.7 Correlations between PrPTSE and infectivity assays	7
6.8 Reductions in infectivity compared with failure to detect at limits of detection	8
6.9 Determining numbers of replicate validations needed to support inferences of reduction in infectivity rather than variations in assay performance	8
6.10 Requirements for step-wise reductions in PrPTSE and infectivity versus whole-process validation	8
Bibliography	9